Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (vol 348, pg 2379, 2003)

被引:0
|
作者
Meis, P. J.
机构
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 391卷 / 02期
关键词
D O I
10.1056/NEJMx240004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (N Engl J Med 2003;348:2379-2385). In the Results section of the Abstract (page 2379), the first sentence should have begun, "Base-line characteristics of the 310 women in the 17P group," rather than "... of the 310 women in the progesterone group." In the second sentence, the first parenthetical should have begun, "(incidence, 36.3 percent in the 17P group," rather than "... in the progesterone group." In the second paragraph of the Introduction (page 2380), the penultimate sentence should have begun, "Another meta-analysis, restricted to trials of 17 alpha-hydroxyprogesterone caproate (17P), a synthetic progestogen," rather than "... a synthetic form of progesterone." In the running heads . . .
引用
收藏
页码:192 / 192
页数:1
相关论文
共 50 条
  • [41] A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins
    Rouse, Dwight J.
    Caritis, Steve N.
    Peaceman, Alan M.
    Sciscione, Anthony
    Thom, Elizabeth A.
    Spong, Catherine Y.
    Varner, Michael
    Malone, Fergal
    Iams, Jay D.
    Mercer, Brian M.
    Thorp, John
    Sorokin, Yoram
    Carpenter, Marshall
    Lo, Julie
    Ramin, Susan
    Harper, Margaret
    Anderson, Garland
    Andrews, W. W.
    Northen, A.
    Sheppard, J.
    Tillinghast, J.
    Allard, D.
    Milluzzi, C.
    Heggie, C.
    Ehrenberg, H.
    Stetzer, B.
    Merlino, A.
    Berkowitz, R.
    Bousleiman, S.
    South, S.
    Paley, L.
    Carmona, V.
    Wapner, R.
    Hoffman, M.
    Talucci, M.
    Wilson, S.
    Tocci, C.
    Lake, M.
    Boggess, K.
    Dorman, K.
    Timlin, S.
    Grobman, W.
    Mallett, G.
    Dinsmoor, M.
    Simon, P.
    Huntley, M.
    Ramos, M.
    Johnson, F.
    Landon, M.
    Latimer, C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (05): : 454 - 461
  • [42] Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate
    Bailit, Jennifer L.
    Votruba, Mark E.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (03) : 219 - 220
  • [43] Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention
    Zhang, Shiyu
    Rascati, Karen L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1667 - 1675
  • [45] Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth
    Kalata, Megan
    Teter, Kellie
    Wagner, Lisa
    Swarr, Vicki
    Witzeman, Kathryn
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2021, 34 (04): : 541 - 546
  • [46] 17α-hydroxyprogesterone caproate for the prevention of preterm delivery -: A cost-effectiveness analysis
    Odibo, Anthony O.
    Stamilio, David M.
    Macones, George A.
    Polsky, Daniel
    OBSTETRICS AND GYNECOLOGY, 2006, 108 (03): : 492 - 499
  • [47] The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate
    Ventolini, Gary
    Duke, Janice
    Po, William
    Barhan, Sheela
    Rhea, Debbie
    Desch, Cheryl
    Istwan, Niki
    Stanziano, Gary
    JOURNAL OF REPRODUCTIVE MEDICINE, 2008, 53 (09) : 667 - 671
  • [48] 17 α-Hydroxyprogesterone Caproate (Makena™)In the Prevention of Preterm Birth
    Emma D. Deeks
    Pediatric Drugs, 2011, 13 : 337 - 345
  • [49] The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate
    Ventolini, Gary
    Duke, Janice
    Po, William
    Barhan, Sheena
    Rhea, Debbie
    Istwan, Niki
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 42S - 43S
  • [50] 17 α-Hydroxyprogesterone Caproate (Makena™) In the Prevention of Preterm Birth
    Deeks, Emma D.
    PEDIATRIC DRUGS, 2011, 13 (05) : 337 - 345